Page last updated: 2024-12-07

cp 41

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

CP 41: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID93513
CHEMBL ID71457
SCHEMBL ID5136933
MeSH IDM0280767

Synonyms (10)

Synonym
cp 41
CHEMBL71457
95215-51-3
3-hydroxy-1-(3-hydroxypropyl)-2-methylpyridin-4-one
4(1h)-pyridinone, 3-hydroxy-1-(3-hydroxypropyl)-2-methyl-
3-hydroxy-1-(3-hydroxypropyl)-2-methyl-4(1h)-pyridinone
cp-41
SCHEMBL5136933
DTXSID70241786
1-(3'-hydroxypropyl)-2-methyl-3-hydroxypyridin-4-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID28984Partition coefficient (logD7.4)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
AID193977The amount of iron-binding when iron chelator administered in the bile duct-cannulated rats.1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
AID15965Partition coefficient (logD7.4)1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.
AID26251Partition coefficient (logD7.4) for iron(III) complexes1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
AID26260Partition coefficient (logD7.4)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
AID135327BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID193974The amount iron excretion in the bile duct-cannulated rats when iron chelator administered subcutaneously at dose 132 mg/kg1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
AID179654Compound was tested in vivo for Iron mobilization efficacy against hepatocytes in normal fasted rats (loaded with [59Fe]-Ferritin).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.
AID19829Partition coefficient (logP)1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.
AID193842The amount iron excretion in the bile duct-cannulated rats when iron chelator administered orally at dose 132 mg/kg1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (66.67)18.2507
2000's2 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]